HK2 and cancer: However, the agents that specifically inhibit glycolytic metabolism have not yielded the expected effect in cancer patients, most likely due to cancer cells developing resistance to the agents or to dose‐limiting side effects.11, 16 Combinational chemotherapies have been widely used to minimise acquired resistance.39 In this study, we demonstrate that the synergy between PD and 2‐DG restrains tumour growth due to the inhibition of the pro‐survival ROS/PI3K/AKT/HIF1α/HK2 pathway (Figure 7).